ARS Pharmaceuticals (SPRY) Invested Capital (2020 - 2026)

ARS Pharmaceuticals (SPRY) posted Invested Capital of $495000.0 for Q1 2021, down 41.35% sequentially from $844000.0 in Q4 2020.

Analysis

ARS Pharmaceuticals (SPRY) Invested Capital (2020 - 2026) Analysis & Trends

ARS Pharmaceuticals has reported Invested Capital for 2 years, with the latest figure at $495000.0 in Q1 2021.

Quarterly Invested Capital changed N/A year-over-year to $495000.0 in Q1 2021, while the trailing twelve-month figure through Dec 2021 was $495000.0 (down 41.35% YoY) and the FY2020 annual result came in at $844000.0, changed N/A from the prior year.
Invested Capital declined to $495000.0 in Q1 2021 per SPRY's latest filing, from $844000.0 in the prior quarter.
Over five years, Invested Capital peaked at $844000.0 in Q4 2020 and troughed at $495000.0 in Q1 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	33.70 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	7.35 Bn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	6.25 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	19.13 Bn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	1.30 Bn
10	ARS Pharmaceuticals	561.12 Mn	417.27 Mn	20.81 Mn	109.19 Mn

Historic Data

Download Data